CDKN3 Overcomes Bladder Cancer Cisplatin Resistance Via LDHA-Dependent Glycolysis Reprogramming

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2022 Apr 7

PMID 35388272

Authors

Mengxuan Li

Nan Che

Yu Jin

Jinhua Li

Wanshan Yang

Affiliations

Soon will be listed here.

Abstract

Background: Aerobic glycolysis plays an important role in bladder cancer (BLCA) progression and chemoresistance. Cyclin-dependent kinase inhibitor-3 (CDKN3), a dual-specificity protein tyrosine phosphatase, has aberrant upregulation in multiple cancer types and is associated with tumorigenesis. However, the role of CDKN3 in BLCA progression and glycolysis has not been elucidated.

Purpose: In this study, we investigated the effect and underlying mechanisms of CDKN3 on bladder cancer chemoresistance.

Results: This study confirmed that CDKN3 was overexpressed in BLCA tissues and promoted proliferation and migration. Additionally, our results showed a CDKN3-dependent mechanism on chemoresistance; chemoresistance cells were transformed into chemosensitivity cells by CDKN3 knockdown. Additionally, we showed that CDKN3 knockdown decreased glycolysis by inhibiting LDHA expression in BLCA chemoresistance cells. The results also proved that LDHA was an important mediator of CDKN3-regulated BLCA resistance. LDHA overexpression reversed glycolysis inhibition and chemosensitivity induced by CDKN3 downregulation.

Conclusion: These data collectively identified a vital role of CDKN3 in glycolysis and chemoresistance by regulating LDHA expression in BLCA cells, providing a possible therapeutic strategy for treating BLCA.

Citing Articles

The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment.

Luan Y, Liang C, Han Q, Zhou X, Yang N, Zhao L BMC Cancer. 2025; 25(1):69.

PMID: 39806313 PMC: 11726977. DOI: 10.1186/s12885-024-13409-w.

SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway.

Gong Y, Gao D, Shi Y, Fan G, Yu X, Yang E Commun Biol. 2025; 8(1):36.

PMID: 39794543 PMC: 11724026. DOI: 10.1038/s42003-024-07284-1.

Advancements in research on lactate dehydrogenase A in urinary system tumors.

Zhuo Z, Wang Y, Xu Y BMC Urol. 2024; 24(1):187.

PMID: 39215270 PMC: 11363645. DOI: 10.1186/s12894-024-01580-y.

Human pan-cancer analysis of the predictive biomarker for the CDKN3.

Chen Y, Li D, Sha K, Zhang X, Liu T Eur J Med Res. 2024; 29(1):272.

PMID: 38720365 PMC: 11077798. DOI: 10.1186/s40001-024-01869-6.

[ formula promotes spinal cord injury repair in rats by activating the YAP/PKM2 signaling axis in astrocytes].

Man H, Wang J, Wu M, Shao Y, Yang J, Li S Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(4):636-643.

PMID: 38708495 PMC: 11073952. DOI: 10.12122/j.issn.1673-4254.2024.04.03.

References

Wang X, Jiang Z, Yang H, Zhang Y, Xu L . Hypoxia-induced FOXO4/LDHA axis modulates gastric cancer cell glycolysis and progression. Clin Transl Med. 2021; 11(1):e279. PMC: 7809603. DOI: 10.1002/ctm2.279. View

Mirzaei S, Gholami M, Khaksary Mahabady M, Nabavi N, Zabolian A, Banihashemi S . Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation. Biomed Pharmacother. 2020; 133:111077. DOI: 10.1016/j.biopha.2020.111077. View

Shi T, Ma Y, Cao L, Zhan S, Xu Y, Fu F . B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. 2019; 10(4):308. PMC: 6450969. DOI: 10.1038/s41419-019-1549-6. View

Ambrosio L, Argenziano M, Cucci M, Grattarola M, de Graaf I, Dianzani C . Carbosilane Dendrimers Loaded with siRNA Targeting Nrf2 as a Tool to Overcome Cisplatin Chemoresistance in Bladder Cancer Cells. Antioxidants (Basel). 2020; 9(10). PMC: 7602517. DOI: 10.3390/antiox9100993. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Zhong C, Chen M, Chen Y, Yao F, Fang W . Loss of DSTYK activates Wnt/β-catenin signaling and glycolysis in lung adenocarcinoma. Cell Death Dis. 2021; 12(12):1122. PMC: 8636471. DOI: 10.1038/s41419-021-04385-1. View

Chen X, Wang P, Ou T, Li J . KLF16 Downregulates the Expression of Tumor Suppressor Gene TGFBR3 to Promote Bladder Cancer Proliferation and Migration. Cancer Manag Res. 2022; 14:465-477. PMC: 8841319. DOI: 10.2147/CMAR.S334521. View

Wang W, Liao K, Guo H, Zhou S, Yu R, Liu Y . Integrated transcriptomics explored the cancer-promoting genes CDKN3 in esophageal squamous cell cancer. J Cardiothorac Surg. 2021; 16(1):148. PMC: 8161916. DOI: 10.1186/s13019-021-01534-7. View

Jin H, Wang J, Shao M, Zhou K, Ma X, Lv X . Down-Regulation of miR-7 in Gastric Cancer Is Associated With Elevated LDH-A Expression and Chemoresistance to Cisplatin. Front Cell Dev Biol. 2020; 8:555937. PMC: 7536350. DOI: 10.3389/fcell.2020.555937. View

10.

Wang D, Chen Z, Lin F, Wang Z, Gao Q, Xie H . OIP5 Promotes Growth, Metastasis and Chemoresistance to Cisplatin in Bladder Cancer Cells. J Cancer. 2018; 9(24):4684-4695. PMC: 6299379. DOI: 10.7150/jca.27381. View

11.

Sun Y, Guan Z, Liang L, Cheng Y, Zhou J, Li J . NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression. Int J Oncol. 2015; 48(1):225-34. DOI: 10.3892/ijo.2015.3256. View

12.

Ying X, Liu B, Yuan Z, Huang Y, Chen C, Jiang X . METTL1-m G-EGFR/EFEMP1 axis promotes the bladder cancer development. Clin Transl Med. 2021; 11(12):e675. PMC: 8694502. DOI: 10.1002/ctm2.675. View

13.

Li W, Zhang L, Wu Y . CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1. Eur Rev Med Pharmacol Sci. 2020; 24(7):3614-3623. DOI: 10.26355/eurrev_202004_20823. View

14.

Mirzaei S, Paskeh M, Hashemi F, Zabolian A, Hashemi M, Entezari M . Long non-coding RNAs as new players in bladder cancer: Lessons from pre-clinical and clinical studies. Life Sci. 2021; 288:119948. DOI: 10.1016/j.lfs.2021.119948. View

15.

Wu T, Yang Y, Zhang B, Zhang Z, Zhou S, Jia G . EDDM3A drives gastric cancer progression by promoting HIF-1α-dependent aerobic glycolysis. Oncogenesis. 2022; 11(1):3. PMC: 8764035. DOI: 10.1038/s41389-022-00379-6. View

16.

Shen Y, Xu J, Pan X, Zhang Y, Weng Y, Zhou D . LncRNA KCNQ1OT1 sponges miR-34c-5p to promote osteosarcoma growth via ALDOA enhanced aerobic glycolysis. Cell Death Dis. 2020; 11(4):278. PMC: 7181648. DOI: 10.1038/s41419-020-2485-1. View

17.

Shi M, Cui J, du J, Wei D, Jia Z, Zhang J . A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Clin Cancer Res. 2014; 20(16):4370-80. PMC: 4134726. DOI: 10.1158/1078-0432.CCR-14-0186. View

18.

Jia G, Wang Y, Lin C, Lai S, Dai H, Wang Z . LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2. J Exp Clin Cancer Res. 2021; 40(1):299. PMC: 8459495. DOI: 10.1186/s13046-021-02090-7. View

19.

Yu H, Yang X, Tang J, Si S, Zhou Z, Lu J . ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2α-Mediated Glycolysis. Mol Ther Nucleic Acids. 2020; 23:27-41. PMC: 7744648. DOI: 10.1016/j.omtn.2020.10.031. View

20.

Xu F, Huang M, Chen Q, Niu Y, Hu Y, Hu P . LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway. Cancer Res. 2021; 81(22):5678-5691. DOI: 10.1158/0008-5472.CAN-21-0281. View